A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii

作者：Siricilla Shajila; Mitachi Katsuhiko; Yang Junshu; Eslamimehr Shakiba; Lemieux Maddie R; Meibohm Bernd; Ji Yinduo; Kurosu Michio^*

来源：Journal of Medicinal Chemistry, 2017, 60(7): 2869-2878.

DOI：10.1021/acs.jmedchem.6b01805

Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most difficult Gram-negative bacteria to treat and eradicate. In a cell-based screening of pleuromutilin derivatives against a drug sensitive A. baumannii strain, new molecules (2-4) exhibit bacteriostatic activity with 3.13 mu g/mL concentration and 1 shows bactericidal activity with an MBC of 6.25 mu g/mL. The pleuromutilin derivative 1 displays strong synergistic effects with doxycycline in a wide range of concentrations. A 35/1 ratio of 1 and doxycycline (1-Dox 35/1) kills drug susceptible A. baumannii with the MBC of 2.0 mu g/mL and an MDR A. baumannii with the MBC of 3.13 mu g/mL. In vitro anti-Acinetobacter activity of 1-Dox 35/1 is superior to that of clinical drugs such as tobramycin, tigecycline, and colistin. The efficacy of 1-Dox 35/1 is evaluated in a mouse septicemia model; treatment of the infected CS7BL/6 mice with 1-Dox 35/1 protects from lethal infection of A. baumannii with an ED50 value of <2.0 mg/kg.

• 出版日期2017-4-13